Stocks Health care ORMP
NASDAQ · Health careOramed Pharmaceuticals Inc. (ORMP)
In fiscal 2025 capital spending exceeded operating cash flow by $9.2M. At June 30, 2026 it held $15.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Oramed Pharmaceuticals Inc.
- Net worth
- Oramed Pharmaceuticals Inc. has a market value (market cap) of $164.5M at the latest share price, and shareholders' equity of $317.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $9.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Dividend
- Oramed Pharmaceuticals Inc. paid dividends of $0.25 per share in fiscal 2025, a yield of 6.32% at the current price.
What Oramed Pharmaceuticals Inc. does
Oramed Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ORMP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2M | $64.1M | $1.50 | -$9.2M |
| 2024 | n/a | -$19.1M | -$0.48 | -$8.4M |
| 2023 | $1.3M | $5.1M | $0.14 | -$10.5M |
| 2022 | $2.7M | -$36.6M | -$0.94 | -$28.4M |
| 2021 | $2.7M | -$23M | $0.78 | -$21.6M |
| 2020 | $2.7M | -$11.5M | $0.56 | -$12.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ORMP ranks in Health care
Dividends
Oramed Pharmaceuticals Inc. paid $0.25 per share in fiscal 2025. At the current price that is a yield of 6.32%.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $0.25 | n/a | n/a |
Latest SEC filings
What Oramed Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 17, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- August 3, 2026
- August 3, 2026Additional proxy material DEFA14A
- August 3, 2026Proxy statement DEF 14A
- June 30, 2026
- June 29, 2026Passive stake changed SCHEDULE 13G/A
- May 19, 2026
- May 15, 2026Late quarterly report notice NT 10-Q
Insider trades
What the people running Oramed Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $225.5K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Hexter JoshuaCOO & CBO | Soldpre-planned (10b5-1) | 30,000 | $135.3K |
| October 1, 2026 | Gabay AvrahamChief Financial Officer | Soldpre-planned (10b5-1) | 20,000 | $90.2K |
| September 24, 2026 | Gabay AvrahamChief Financial Officer | Received as pay | 209,291 | - |
| September 24, 2026 | Kidron MiriamChief Scientific Officer, Director | Received as pay | 208,125 | - |
| September 24, 2026 | Kidron MiriamChief Scientific Officer, Director | Received as pay | 209,291 | - |
| September 24, 2026 | Hexter JoshuaCOO & CBO | Received as pay | 75,455 | - |
| September 24, 2026 | Hexter JoshuaCOO & CBO | Received as pay | 209,291 | - |
| September 24, 2026 | Kidron NadavPresident and CEO, Director | Received as pay | 349,497 | - |
Who owns ORMP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Oramed Pharmaceuticals Inc.13D, may seek influence | 49.9% | May 14, 2026 |
| Aquamarine Financial (Cayman) Ltd13G, passive | 6.04% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 84 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Mercer Global Advisors Inc | 3,810,540 | +1,900,000 |
| Aquamarine Financial (Cayman) Ltd | 2,512,175 | +399,863 |
| Gem Investment Advisors, LLC | 1,998,802 | +358,733 |
| BlackRock, Inc. | 1,608,111 | +1,515,919 |
| Murchinson Ltd. | 1,290,294 | -25,000 |
| BML Capital Management, LLC | 866,269 | -2,300,962 |
| Boothbay Fund Management, LLC | 578,638 | -22,078 |
| Geode Capital Management, LLC | 500,690 | +476,408 |
| Goldman Sachs Group Inc | 253,293 | new |
| State Street Corp | 242,100 | new |
| Rathbones Group PLC | 233,018 | -233,018 |
| Vanguard Portfolio Management LLC | 229,882 | new |
| Dimensional Fund Advisors LP | 202,609 | +44,400 |
| Northern Trust Corp | 184,920 | new |
| Renaissance Technologies LLC | 183,800 | +36,100 |
| Wells Fargo & Company | 166,000 | +8,414 |
| Bank of America Corp | 150,694 | +4,542 |
| Strs Ohio | 133,800 | new |
| Jane Street Group, LLC | 113,349 | +60,809 |
| O'Shaughnessy Asset Management, LLC | 102,962 | -13,401 |
Insiders
8 insiders reported holding 8,390,115 shares in total, about $33.2M at the last price.
| Holder | Shares |
|---|---|
| Kidron NadavPresident and CEO, Director | 4,140,505 |
| Kidron MiriamChief Scientific Officer, Director | 1,550,554 |
| Hexter JoshuaCOO & CBO | 1,328,130 |
| Gabay AvrahamChief Financial Officer | 861,076 |
| Mayer ArieDirector | 168,009 |
| Shapiro BenjaminDirector | 123,220 |
| Aghion DanielDirector | 113,441 |
| Reznick YehudaDirector | 105,180 |
Questions about ORMP
What does Oramed Pharmaceuticals Inc. do?
Oramed Pharmaceuticals Inc. is a company in the Health care sector, listed on NASDAQ as ORMP. Its shares trade on NASDAQ under the ticker ORMP.
What is Oramed Pharmaceuticals Inc.'s net worth?
Oramed Pharmaceuticals Inc. has a market value (market cap) of $164.5M at the latest share price, and shareholders' equity of $317.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Oramed Pharmaceuticals Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $174.9M.
When did Oramed Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
Does Oramed Pharmaceuticals Inc. pay a dividend?
Yes. Oramed Pharmaceuticals Inc. paid dividends of $0.25 per share in fiscal 2025, a yield of 6.32% at the current price.
Similar companies
Compare ORMP with
Follow ORMP
Get an email when Oramed Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Oramed Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.